Glaucoma Research Foundation to Recognize Santen Pharmaceutical at Annual Gala in San Francisco

Santen Pharmaceutical will receive the Glaucoma Research Foundation's Catalyst Award at the Glaucoma 360 Annual Gala on February 2, 2023, in San Francisco, the foundation's President and CEO Thomas M. Brunner announced. 

Santen is being recognized for their "steadfast commitment to bringing innovation to the field of glaucoma," according to a Glaucoma Research Foundation news release.

“We are delighted to have an opportunity to highlight the Santen team and their work serving unmet patient needs through their development of innovative solutions to treat glaucoma and improve the quality of life for patients around the world,” said Mr. Brunner.

Peter Sallstig, MD, MBA, the Global Head of Santen’s Product Development Division and the Chief Medical Officer, will accept the award on behalf of Santen.

“Santen is extremely proud and honored to receive this prestigious award. Our team is guided by a passion for bringing innovation to eye care and contributing to the well-being of patients and their families worldwide. It has been a great pleasure to partner with Glaucoma Research over the past 20 years and support their many patient education and research initiatives,” said Dr. Sallstig.

The annual gala launches Glaucoma 360, a series of events held at the Westin St. Francis Hotel that includes the New Horizons Forum, a full-day meeting dedicated to innovations in glaucoma therapy, and concludes with two continuing medical education symposia for ophthalmologists and optometrists. 

All proceeds from Glaucoma 360 support Glaucoma Research Foundation’s research and education programs. To learn more or to register, visit: www.glaucoma360.org.